Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

1.

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.

Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.

2.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.

3.

CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.

Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM.

Neurology. 2012 Mar 6;78(10):709-19. doi: 10.1212/WNL.0b013e318248e568. Epub 2012 Feb 22.

4.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

5.

Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.

Babić Leko M, Borovečki F, Dejanović N, Hof PR, Šimić G.

J Alzheimers Dis. 2016;50(3):765-78. doi: 10.3233/JAD-150705.

PMID:
26836160
6.

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.

J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.

7.

Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.

Mroczko B, Groblewska M, Zboch M, Muszyński P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2015;43(3):1031-7. doi: 10.3233/JAD-141050.

PMID:
25159667
8.

Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.

Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.

Alzheimers Res Ther. 2015 Sep 17;7(1):59. doi: 10.1186/s13195-015-0142-1.

9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
10.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
11.

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2016 May 1;73(5):561-71. doi: 10.1001/jamaneurol.2016.0086.

PMID:
27018940
12.

Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.

Almeida RP, Schultz SA, Austin BP, Boots EA, Dowling NM, Gleason CE, Bendlin BB, Sager MA, Hermann BP, Zetterberg H, Carlsson CM, Johnson SC, Asthana S, Okonkwo OC.

JAMA Neurol. 2015 Jun;72(6):699-706. doi: 10.1001/jamaneurol.2015.0098.

13.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

14.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
15.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
16.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
17.

Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.

Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2016;51(4):1085-97. doi: 10.3233/JAD-150937.

PMID:
26967213
18.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative..

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

19.

Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.

Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, Brajenovic-Milic B, Hecimovic H, Titlic M, Trkanjec Z, Demarin I, Hecimovic S.

Acta Neurobiol Exp (Wars). 2012;72(3):264-71.

20.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

PMID:
22677492

Supplemental Content

Support Center